The effect of NAC in psychotic patients

Efficacy of risperidone/ NAC versus risperidone on cognitive functioning over the three months of treatment for psychotic disorder: a double-blind randomized clinical trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240309061224N1

Enrollment

Registered

2024-04-15

Start date

2024-04-07

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: The schizophrenic disorders. Condition 2: Delusional disorders. Condition 3: Schizoaffective disorders. Condition 4: Mental and behavioural disorders. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted Delusional disorders is a medical classification as listed by WHO under the range - Mental, Behavioral and Neurodevelopmental disorders Schizoaffective diso

Interventions

Intervention 1: Intervention group: give NAC. The antipsychotic drug risperidone four milligrams daily along with six hundred milligrams of the antioxidant N-acetylcysteinePreparation of the drug fro

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Filling out the consent form by the patient's guardian and having consent for the patient to enter the research project Being in the category of psychotic diseases : Participants had to meet criteria for a DSM-V psychotic disorder, including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, depression with psychosis, substance-induced psychotic disorder. The patient is not dangerous and does not pose a danger to herself or others

Exclusion criteria

Exclusion criteria: Dissatisfaction : Lack of consent, not filling out the consent form by the patient's guardian and not having consent for the patient to enter the research project Being dangerous to yourself or others: The dangerousness of the patient and the high probability of having a risk of life and injury to oneself and others

Design outcomes

Primary

Measure	Time frame
Positive and negative symptoms. Timepoint: (0) On arrival - 3 and 6 months after the intervention. Method of measurement: Interviews and psychological tests.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPilafkan Nasrin MD

Zanjan University of Medical Sciences

drsseyedi@gmail.com+98 24 3354 2403

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026